Sort   by:  
 Page size 
UnknownTyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.
Not available
S-EPMC11819001 | biostudies-literature
UnknownReal-world experience of novel multiple myeloma treatments in a large, single-center cohort in Finland.
Not available
S-EPMC10660399 | biostudies-literature
UnknownDasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
Not available
S-EPMC4365700 | biostudies-literature
UnknownMutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia.
Not available
S-EPMC7013270 | biostudies-literature
UnknownRUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses.
Not available
S-EPMC8024199 | biostudies-literature
UnknownEpigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation.
Not available
S-EPMC9021312 | biostudies-literature
UnknownNovel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing.
Not available
S-EPMC4423219 | biostudies-literature
UnknownMolecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI.
Not available
S-EPMC8324471 | biostudies-literature
UnknownImmunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line.
Not available
S-EPMC6685516 | biostudies-literature
UnknownTreatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Not available
S-EPMC10997502 | biostudies-literature
Sort   by:  
 Page size